Robeco Institutional Asset Management B.V. Sells 5,179 Shares of Incyte Co. (NASDAQ:INCY)

Robeco Institutional Asset Management B.V. reduced its position in Incyte Co. (NASDAQ:INCY - Free Report) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,260,787 shares of the biopharmaceutical company's stock after selling 5,179 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.65% of Incyte worth $87,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of INCY. Point72 Asset Management L.P. bought a new position in shares of Incyte in the third quarter worth $156,611,000. Mizuho Securities USA LLC boosted its holdings in shares of Incyte by 13,814.7% in the third quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company's stock worth $132,207,000 after acquiring an additional 1,985,726 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Incyte by 29.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,220 shares of the biopharmaceutical company's stock worth $106,369,000 after acquiring an additional 364,169 shares during the period. Barclays PLC boosted its holdings in shares of Incyte by 8.1% in the third quarter. Barclays PLC now owns 1,031,932 shares of the biopharmaceutical company's stock worth $68,208,000 after acquiring an additional 77,542 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Incyte by 0.9% in the third quarter. Swiss National Bank now owns 483,274 shares of the biopharmaceutical company's stock worth $31,944,000 after acquiring an additional 4,500 shares during the period. 96.97% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on INCY. William Blair reissued an "outperform" rating on shares of Incyte in a research note on Friday, December 13th. StockNews.com lowered Incyte from a "strong-buy" rating to a "buy" rating in a research note on Friday, December 13th. Wells Fargo & Company lifted their price objective on Incyte from $68.00 to $70.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. JMP Securities reissued a "market perform" rating on shares of Incyte in a research note on Tuesday, January 14th. Finally, Bank of America raised Incyte from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $68.00 to $90.00 in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $75.71.

Insider Buying and Selling at Incyte

In other news, EVP Steven H. Stein sold 12,352 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the sale, the executive vice president now directly owns 66,967 shares of the company's stock, valued at $4,867,831.23. The trade was a 15.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vijay K. Iyengar sold 6,043 shares of the business's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $75.38, for a total value of $455,521.34. Following the completion of the sale, the executive vice president now directly owns 30,658 shares in the company, valued at approximately $2,311,000.04. This represents a 16.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,375 shares of company stock valued at $1,737,578. 17.60% of the stock is currently owned by corporate insiders.

Incyte Trading Up 0.1 %

NASDAQ:INCY traded up $0.05 during mid-day trading on Thursday, reaching $73.77. 1,237,654 shares of the company's stock traded hands, compared to its average volume of 1,384,729. Incyte Co. has a 12-month low of $50.35 and a 12-month high of $83.95. The firm has a market capitalization of $14.21 billion, a price-to-earnings ratio of 526.97, a PEG ratio of 0.53 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.87 and a quick ratio of 1.82. The company has a 50 day moving average price of $71.71 and a 200-day moving average price of $68.71.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.12). The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.08 billion. Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The business's revenue was up 23.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.91 earnings per share. On average, sell-side analysts predict that Incyte Co. will post 0.39 earnings per share for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.